Article Text

Download PDFPDF

4CPS-253 Community pharmacy-based eGFR screening for early detection of chronic kidney disease in high-risk patients
  1. J Papastergiou1,
  2. M Omran1,
  3. B Van Den Bemt2
  1. 1University of Toronto, Leslie Dan Faculty of Pharmacy, Toronto, Canada
  2. 2St. Maartenskliniek Nijmegen, Department of Pharmacy, Nijmegen, The Netherlands


Background Chronic kidney disease (CKD) is a condition presenting with long-term slow progression of structural and/or functional damage to the kidneys. Early detection is key to improved outcomes. Point-of-care eGFR screening technology allows for detection of abnormal kidney function in the community pharmacy setting.

Purpose To evaluate the effectiveness of a community pharmacist-directed point-of-care screening programme and to identify the prevalence of CKD in high-risk patients.

Material and methods Patients with at least one CKD risk factor were identified at four community pharmacies in British Columbia. They provided a sample of peripheral blood via a self-administered finger-prick and analytical data to assess kidney function that was reported including BUN, serum creatinine, and electrolytes by the HealthTab screening system. The eGFR was calculated according to the CKD-EPI formula. Once results were available the pharmacist conducted a comprehensive review with the patient and recommended certain follow-up actions if appropriate.

Results Six-hundred and forty-two participants were screened over a 6 month period. Mean age was 60 years and females accounted for 55% of the study population. CKD risk factors included diabetes (30%), hypertension (45%), cardiovascular disease (12%), family history of kidney disease (13%), age over 55 years (68%) and an Aboriginal, Asian, South Asian or African ethnic background (82%). 11.5% of patients had eGFR values lower than 60 mL/min (abnormal renal function) and 34% had an eGFR between 60 mL/min and 89 mL/min (minimally reduced renal function). Overall pharmacists’ actions included blood pressure check (98%), education on CKD and risk factors (89%), medication review (72%) and physician follow-up (38%).

Conclusion These results illustrate the prevalence of abnormal renal function among undiagnosed, high-risk patients in the community. Pharmacists, as the most accessible healthcare practitioners, are ideally positioned to utilise novel point-of care technologies to improve access to CKD screening and increase awareness around the importance of early detection.

References and/or acknowledgements This project was funded through a partnership between the BC Ministry of Health and The Kidney Foundation of Canada.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.